Search Results for "Apidra"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Apidra. Results 1 to 8 of 8 total matches.

Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006  (Issue 1233)
Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin ...
Insulin glulisine (Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog). All three have a more rapid onset and shorter duration of action than regular human insulin. Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.
Med Lett Drugs Ther. 2006 Apr 24;48(1233):33-4 |  Show IntroductionHide Introduction

Rapid-Acting Insulin Analogues

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009  (Issue 1327)
. Insulin glulisine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther 2006; 48:33. 4. P Rossetti ...
Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous injection, insulin pump or intravenous administration. All three cost more than regular insulin.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):98 |  Show IntroductionHide Introduction

An Inhaled Insulin (Afrezza)

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
(Novolog), insulin glulisine (Apidra), and insulin lispro (Humalog). All three are approved for use ...
The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin (Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in combination with long-acting insulin. Another inhaled, rapid-acting insulin (Exubera) was approved in 2006 for the same indication, but was withdrawn from the market the following year.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):34-5 |  Show IntroductionHide Introduction

Fiasp - Another Insulin Aspart Formulation for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018  (Issue 1537)
– 10 mL vial; 3 mL Solostar pen 197.10 Apidra (Sanofi) Insulin lispro – Humalog (Lilly) 3, 10 mL ...
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart (Novolog).
Med Lett Drugs Ther. 2018 Jan 1;60(1537):6-7 |  Show IntroductionHide Introduction

Lyumjev - A New Insulin Lispro for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
FlexTouch3 111.80 Insulin Glulisine Apidra (Sanofi) 100 units/mL 10 mL vials 284.00 3 mL SoloStar3 109.70 ...
The FDA has approved insulin lispro-aabc (Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog), for treatment of type 1 and type 2 diabetes in adults. Fiasp, a faster-acting formulation of insulin aspart (Novolog), was approved in 2017.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):162-3 |  Show IntroductionHide Introduction

Insulins for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
FlexTouch3 111.80 Insulin glulisine – Apidra 100 units/mL 10 mL vials 10-30 mins 60 mins 4-5 hrs 284.00 ...
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin is the preferred first-line treatment, but most patients with type 2 diabetes eventually require multidrug therapy and/or insulin to achieve glycemic control.
Med Lett Drugs Ther. 2019 May 6;61(1571):65-8 |  Show IntroductionHide Introduction

Inhaled Insulin (Exubera)

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2006  (Issue 1239)
subcutaneous insulin analogs such as insulin lispro (Humalog), aspart (Novolog) or glulisine (Apidra). 5 ...
An inhaled, dry-powder formulation of rapid-acting human insulin (Exubera - Pfizer) has been approved by the FDA for treatment of adults with type 1 or type 2 diabetes.
Med Lett Drugs Ther. 2006 Jul 17;48(1239):57-8 |  Show IntroductionHide Introduction

Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
glulisine – Apidra (Sanofi) 100 units/mL 10 mL vials 3 mL SoloStar2 10-30 mins 60 mins 4-5 hrs ▶ Rapid ...
View the Expanded Table: Some Available Insulins
Med Lett Drugs Ther. 2019 May 6;61(1571):e73-7 |  Show IntroductionHide Introduction